Pfizer Inc. (PFE)

Quick facts

Marketed products

• Prevnar family · Immunology · revenue 6494
  Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
• Prevnar 20 · Immunology · revenue 6400
  20-valent pneumococcal conjugate vaccine that elicits immune responses against 20 Streptococcus pneumoniae serotypes
• Comirnaty · Infectious Disease · revenue 5400
  Comirnaty is an mRNA-based vaccine.
• Ibrance · Oncology · revenue 4500
  Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer.
• COMIRNATY intramuscular injection · revenue 4367.0
• Famtozinameran 12 Years of age and older · Infectious Disease · revenue 4367
  Famtozinameran works by targeting the SARS-CoV-2 virus.
• Palbociclib in combination with AI · Oncology · revenue 4122
• PF-06863135 + lenalidomide · Oncology · revenue 2951
• Nivolumab and Ipilimumab · revenue 2900
• Nivolumab and/or Ipilimumab · revenue 2900
• Venetoclax; Rituximab · Oncology · revenue 2583
• Paxlovid (Copackaged) · Immunology · revenue 2362.0
  Paxlovid works by binding to the main protease enzyme of the SARS-CoV-2 virus, preventing it from replicating.
• Talazoparib with enzalutamide · Oncology · revenue 2194
• Xeljanz · Immunology · revenue 1800
  Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs.
• Abiraterone Acetate · Oncology · revenue 1500
  Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells.
• Nurtec Odt · Neuroscience · revenue 1424
  Rimegepant is a calcitonin gene-related peptide receptor antagonist.
• Immuno-oncology (IO) · Oncology · revenue 1301
• Lorbrena · Oncology · revenue 1100
  Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow.
• In open-label phase: treatment with tofacitinib · Immunology · revenue 1087
• Xeljanz · revenue 1087
  Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation.
• Pristiq · Neuroscience · revenue 1041.0
  Potentiates serotonin and norepinephrine in CNS through reuptake inhibition.
• Abrysvo · Infectious Disease · revenue 1033
  ABRYSVO is a vaccine that protects against respiratory syncytial virus (RSV).
• Lipitor · Metabolic · revenue 1000.0
  Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis.
• Premarin · Metabolic · revenue 1000.0
• Inlyta · Oncology · revenue 923
  Inlyta works by blocking the activity of the mast/stem cell growth factor receptor Kit, which is involved in the growth and spread of cancer cells.
• Adcetris · Oncology · revenue 900
  Adcetris works by binding to cancer cells that express CD30 and delivering a toxic payload to kill the cells.
• Chemotherapy · Other · revenue 798
• Lorlatinib with chemotherapy 2 · Oncology · revenue 798
• PF-07104091 monotherapy dose expansion (ovarian) · Oncology · revenue 798
• Rimegepant 75mg every other day dosing · Neuroscience · revenue 798
  Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines.
• Ribociclib (Dose #2) · revenue 787
• Braftovi · Oncology · revenue 716
  Braftovi works by blocking the activity of a specific protein called BRAF that is involved in cancer cell growth.
• Infliximab [infliximab biosimilar 3] · Oncology · revenue 646
  Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions.
• Zavicefta, Ceftazidime-Avibactam · Infectious Disease · revenue 638
• Bosulif · Oncology · revenue 611
  Bosulif blocks the abnormal tyrosine kinase activity in cancer cells, inhibiting their growth and proliferation.
• Bosulif · Oncology · revenue 611
  Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells.
• Bosutinib capsule · revenue 611
• Tukysa · Oncology · revenue 463
  Tukysa blocks the activity of ERBB2 and ERBB3 proteins, which are involved in cancer cell growth and spread.
• Aromasin · Oncology · revenue 450
  Aromasin works by blocking the aromatase enzyme, which is responsible for converting androgens into estrogens.
• Omnitrope · revenue 446
  Somatropin binds dimeric GH receptors on target cells, inducing intracellular signaling and GH-dependent protein synthesis including IGF-1.

Phase 3 pipeline

• talazoparib plus enzalutamide · revenue 2194
• Axitinib plus Toripalimab · revenue 923
• Docetaxel monotherapy · revenue 798

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Pfizer Inc. portfolio CI brief
• Pfizer Inc. pipeline updates RSS